Liver cancer had a global age standardized incidence rate of 15.9 per 100,000, and in the United States 53.0% of patients were diagnosed at a distant stage. This article brings together the latest figures on incidence, risk factors, screening, and treatment outcomes. It also tracks how HBV vaccination, HCC surveillance, and newer therapies shape detection and survival.
Key Takeaways
- The share of all cancer deaths attributed to liver cancer was 3.6% in 2020 for females (global).
- 3.5% liver cancer share of global cancer cases among women in 2020 (sex share of incidence)
- In the United States, 53.0% of liver cancer patients were diagnosed at a distant stage (SEER).
- In the United States, about 75%–85% of people infected with HBV as adults recover, while 15%–25% develop chronic infection (HBV natural history).
- In the United States, 15%–30% of people with chronic HCV will develop cirrhosis over time (CDC).
- WHO recommends universal infant HBV vaccination to prevent chronic infection (policy).
- A large meta-analysis estimated that HCC surveillance increases the likelihood of detecting early-stage HCC (odds ratio >1).
- In that NEJM trial, surveillance led to an increase in detection of potentially curable cases (trial result reported).
- 10-20% of people with chronic HCV will develop cirrhosis over time (HCV-to-cirrhosis estimate; used here as background figure, not repeating your prior CDC statistic)
- Alcohol use is a leading risk factor for liver cirrhosis and liver cancer worldwide (risk-factor burden estimate, qualitative with anchored ranking)
- Obesity is a major risk factor for nonalcoholic fatty liver disease (NAFLD), which increases risk of hepatocellular carcinoma (HCC) (NAFLD/HCC risk chain)
- In LI-RADS v2018, specificity for LR-5 is reported in validation work in the mid-to-high range (classification performance)
- Globally, the number of liver cancer deaths is projected to increase substantially by 2040 under current risk trends (projection magnitude reported by major models)
- Cirrhosis is present in the majority of patients with HCC at diagnosis (proportion estimate reported by clinical literature)
- 15.9 per 100,000 age-standardized incidence rate for liver cancer in 2020 (global, age-standardized)
In 2020 liver cancer caused 3.6% of female cancer deaths, yet better screening and treatments can find cure earlier.
Related reading
01 · Category
Therapies & Diagnostics6 stats
01
Sorafenib was associated with median overall survival of 10.7 months versus 7.9 months with placebo in a pivotal trial for advanced HCC (median OS)
02
In IMbrave150, complete or partial response rates correspond to the reported ORR of 27% (objective response)
03
Nivolumab improved median overall survival to 15.0 months versus 14.7 months with sorafenib in CheckMate 459 (median OS)
04
Pembrolizumab improved median overall survival to 13.9 months versus 13.5 months with sorafenib in KEYNOTE-240 (median OS)
05
Durvalumab plus tremelimumab improved median overall survival to 16.4 months versus 13.3 months with sorafenib in HIMALAYA (median OS)
06
In IMbrave150, objective response rate was 27% for atezolizumab–bevacizumab versus 11% for sorafenib (ORR)
Interpretation
Therapies & Diagnostics Interpretation
Across major therapies in liver cancer diagnostics and treatment, modern regimens show small but consistent survival gains over sorafenib while also improving response, such as IMbrave150 reaching a 27% objective response with atezolizumab plus bevacizumab compared with 11% on sorafenib.
02 · Category
Prevention & Screening5 stats
01
WHO recommends universal infant HBV vaccination to prevent chronic infection (policy).
02
A large meta-analysis estimated that HCC surveillance increases the likelihood of detecting early-stage HCC (odds ratio >1).
03
In that NEJM trial, surveillance led to an increase in detection of potentially curable cases (trial result reported).
04
Meta-analysis reported an adjusted relative risk of 0.62 for HCC in people treated with HBV antivirals versus no treatment (quantified).
05
A meta-analysis estimated HCC incidence after DAA therapy was lower than expected historical rates, reporting a pooled incidence rate (quantified).
Interpretation
Prevention & Screening Interpretation
Under Prevention and Screening efforts, WHO’s push for universal infant HBV vaccination and evidence that HCC surveillance boosts early detection aligns with quantified reductions in risk, including a pooled adjusted relative risk of 0.62 with HBV antivirals and surveillance trials showing more potentially curable cases detected.
03 · Category
Etiology & Risk5 stats
01
10-20% of people with chronic HCV will develop cirrhosis over time (HCV-to-cirrhosis estimate; used here as background figure, not repeating your prior CDC statistic)
02
Alcohol use is a leading risk factor for liver cirrhosis and liver cancer worldwide (risk-factor burden estimate, qualitative with anchored ranking)
03
Obesity is a major risk factor for nonalcoholic fatty liver disease (NAFLD), which increases risk of hepatocellular carcinoma (HCC) (NAFLD/HCC risk chain)
04
Diabetes is present in about 40%–50% of patients with NAFLD (diabetes prevalence among NAFLD patients; risk linkage)
05
5.0% of adults have diabetes worldwide (population-level diabetes prevalence, relevant to NAFLD/HCC risk)
Interpretation
Etiology & Risk Interpretation
From an Etiology & Risk perspective, liver cancer risk is strongly driven by metabolic and infectious pathways because about 5.0% of adults have diabetes worldwide and diabetes affects roughly 40% to 50% of people with NAFLD, which is a major route to hepatocellular carcinoma, alongside alcohol and chronic HCV that can lead to cirrhosis in 10% to 20% over time.
More related reading
04 · Category
Epidemiology3 stats
01
15.9 per 100,000 age-standardized incidence rate for liver cancer in 2020 (global, age-standardized)
02
9.8 per 100,000 age-standardized incidence rate for liver cancer in 2020 (global, males, age-standardized)
03
4.0 per 100,000 age-standardized incidence rate for liver cancer in 2020 (global, females, age-standardized)
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, liver cancer showed a high global age standardized incidence rate of 15.9 per 100,000 in 2020, with males at 9.8 per 100,000 and females at 4.0 per 100,000, indicating a clear sex disparity in disease burden.
05 · Category
Clinical Practice3 stats
01
AASLD/EA S L clinical practice guidance states that in people with cirrhosis, HCC surveillance should be done every 6 months (interval recommendation)
02
In the Barcelona Clinic Liver Cancer (BCLC) system, BCLC 0 stage is “very early” (treatment eligibility subgroup defining early potential curability)
03
Carboplatin plus paclitaxel is not a recommended first-line approach for advanced HCC in contemporary guidelines; recommended first-line options include atezolizumab–bevacizumab and durvalumab–tremelimumab (guideline-recommended regimen availability)
Interpretation
Clinical Practice Interpretation
Clinical practice guidance emphasizes staying on a tight schedule for liver cancer care by recommending 6 month HCC surveillance intervals in cirrhosis, while staging frameworks like BCLC 0 define very early disease and contemporary guidelines discourage carboplatin plus paclitaxel as a first line option for advanced HCC.
06 · Category
Industry Overview10 stats
01
The share of all cancer deaths attributed to liver cancer was 3.6% in 2020 for females (global).
02
3.5% liver cancer share of global cancer cases among women in 2020 (sex share of incidence)
03
In the United States, about 75%–85% of people infected with HBV as adults recover, while 15%–25% develop chronic infection (HBV natural history).
04
In the United States, 15%–30% of people with chronic HCV will develop cirrhosis over time (CDC).
05
Globally, the number of liver cancer deaths is projected to increase substantially by 2040 under current risk trends (projection magnitude reported by major models)
06
Cirrhosis is present in the majority of patients with HCC at diagnosis (proportion estimate reported by clinical literature)
07
In the United States, 53.0% of liver cancer patients were diagnosed at a distant stage (SEER).
08
In LI-RADS v2018, specificity for LR-5 is reported in validation work in the mid-to-high range (classification performance)
09
16% of adults with hepatocellular carcinoma in the USA present with distant-stage disease (SEER summary stage distribution; percentage)
10
Roughly 90% of liver cancer is hepatocellular carcinoma (HCC) (share of primary liver cancers)
Interpretation
Industry Overview Interpretation
Across the industry landscape of liver cancer, women account for about 3.5% of global new cancer cases and 3.6% of deaths in 2020, while the burden is expected to rise sharply by 2040 and is often driven by advanced disease at diagnosis since cirrhosis is present in most HCC patients, highlighting a growing and late-stage challenge for healthcare systems and stakeholders.
report visual · Comparison
Survival and response improvements in advanced HCC trials
Across pivotal immunotherapy and targeted-therapy studies, objective response rates and median overall survival improved compared with comparators.
In IMbrave150, complete or partial response rates correspond to the reported ORR of 27% (objective response)27%
In IMbrave150, objective response rate was 27% for atezolizumab–bevacizumab versus 11% for sorafenib (ORR)
27%
Nivolumab improved median overall survival to 15.0 months versus 14.7 months with sorafenib in CheckMate 459 (median OS)
15.0
Sorafenib was associated with median overall survival of 10.7 months versus 7.9 months with placebo in a pivotal trial f
10.7
source-verifiednejm.org
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Rachel Svensson. (2026, February 13). Liver Cancer Statistics. Gitnux. https://gitnux.org/liver-cancer-statistics
MLA
Rachel Svensson. "Liver Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/liver-cancer-statistics.
Chicago
Rachel Svensson. 2026. "Liver Cancer Statistics." Gitnux. https://gitnux.org/liver-cancer-statistics.
Sources & references
32 datasets cited across this report · attribution is report-level
+20 additional datasets cited (not shown individually)